• Sandoz Germany launches Vitaros®, an innovative new patent-protected therapy for leading urology disorder erectile dysfunction (ED)
• First topical therapy approved for treatment of ED, characterized by ease of use, rapid onset and high tolerability
• Launch in Sandoz’s largest EU market further demonstrates company commitment to meeting unmet medical need across key therapeutic areas

Holzkirchen, August 18, 2014 – Sandoz, the generic pharmaceuticals division of Novartis, today announces the launch in Germany of Vitaros®, an innovative new …